| # | Side effect | Count |
|---|---|---|
| 0 | DRUG INTERACTION | 8 |
| 1 | PRODUCT USE IN UNAPPROVED INDICATION | 7 |
| 2 | DRUG HALF-LIFE INCREASED | 4 |
| 3 | IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | 4 |
| 4 | COVID-19 | 3 |
| 5 | COVID-19 PNEUMONIA | 3 |
| 6 | DRUG CLEARANCE DECREASED | 3 |
| 7 | BLOOD CREATININE INCREASED | 2 |
| 8 | DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 2 |
| 9 | DRUG LEVEL INCREASED | 2 |
| # | Side effect | Count | Frequency |
|---|---|---|---|
| 0 | DRUG HALF-LIFE INCREASED | 4 | 0.0351 |
| 1 | DRUG CLEARANCE DECREASED | 3 | 0.0023 |
| 2 | IMMUNOSUPPRESSANT DRUG LEVEL INCREASED | 4 | 0.0012 |
| 3 | IMMUNE-MEDIATED DERMATITIS | 1 | 0.0010 |
| 4 | IMMUNE-MEDIATED HYPOTHYROIDISM | 1 | 0.0009 |
| 5 | IMMUNOSUPPRESSANT DRUG LEVEL DECREASED | 1 | 0.0008 |
| 6 | IMMUNE-MEDIATED LUNG DISEASE | 1 | 0.0005 |
| 7 | ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS | 1 | 0.0004 |
| 8 | IMMUNE-MEDIATED MYOSITIS | 1 | 0.0004 |
| 9 | IMMUNE-MEDIATED ENTEROCOLITIS | 1 | 0.0003 |